
Oregon venture capital fund investing early in minority and women-led startups
Australian-managed evergreen fund investing in later-stage biotech with measurable impact

Run from Australia, with further offices in strategic regions, the Bio Capital Impact Fund is an evergreen, open-ended fund for biotechnology investments. The fund has no end date and no ceiling on its value, so it can keep investing as opportunities arise rather than working through a fixed life.
The fund invests in innovative and disruptive technologies in biotechnology, covering medical, agricultural and industrial applications. It focuses on high-growth, diversified, later-stage investments internationally, and it describes its aim as backing companies whose work makes lives better or improves society as a whole.
The fund's structure offers reinvestment pathways and a structure that can be tailored for significant investors with a long-term horizon. Income flows directly to investors, and the fund says management remuneration is aligned with investors' interests. It also describes a rigorous process for selecting investments, followed by active, ongoing involvement in each one.
The fund says its arrangements are tax-efficient, citing a tax-neutral location and tax-effective arrangements at all levels. The fund describes these as part of its investor terms.
Beyond capital, the fund offers ongoing strategic support to its investments. It says it builds alliances and collaborations with partners such as pharmaceutical companies, medical research institutes and universities, which it presents as a way of delivering connections that investors did not expect.
Its measurement of impact is judged by internationally accredited organisations. The management team has worked in commercialisation, licensing, fund building and portfolio management across Asia, Europe and North America.
Bio Capital Impact Fund is an open-ended, evergreen fund managed from Australia, with satellite offices in other regions. It has no sunset date and no cap on its size, so it can make investments as opportunities arise.
The fund invests in biotechnology that it believes improves lives or benefits society. It says impact is judged by internationally accredited organisations.
Investors with a long-term view, and biotech companies in medical, agricultural and industrial fields.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Bio Capital Impact Fund.
Similar listings buyers compare against this one.

Oregon venture capital fund investing early in minority and women-led startups

A growth capital provider to commercial-stage pharmaceutical and medical device companies

Investment adviser managing public and private healthcare equity strategies for investors worldwide

Israeli venture fund investing in fintech start-ups at seed and growth stages

Biotechnology investment firm that creates and funds therapeutics companies, including via its BioImpact arm

A venture firm that backs enterprise technology founders from the earliest idea onwards

Asia-based private equity investor spanning buyouts, private credit and growth capital in Asia and North America

Deep tech venture fund backing patent-based science startups in the US Southwest and Northern Europe
Everything here links back to the same verified catalogue. Pick your next stop.